ClinicalTrials.Veeva

Menu

Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib

C

Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo

Status

Enrolling

Conditions

Advanced ALK/ROS1-positive NSCLC
ALK-positive Non-small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small-Cell Lung (NSCLC)
Cognitive Dysfunction
Depression
Lung Adenocarcinoma

Study type

Observational

Funder types

Other

Identifiers

NCT07633626
Vortioxetina

Details and patient eligibility

About

This observational study evaluates whether vortioxetine - an antidepressant medication with cognitive-enhancing properties - can reduce the neurological and cognitive side effects associated with lorlatinib treatment in patients with non-small cell lung cancer (NSCLC) harboring ALK or ROS1 gene rearrangements.

Lorlatinib is a highly effective third-generation tyrosine kinase inhibitor, but it causes neuropsychological adverse events (NAEs) in approximately 42% of patients, including cognitive impairment, mood changes, and speech disturbances. Vortioxetine has demonstrated cognitive improvement in depressed patients and in preclinical models of androgen deprivation therapy-induced cognitive impairment.

Twenty-four adult patients with ALK/ROS1-positive NSCLC receiving lorlatinib as standard care and prescribed vortioxetine (10-20 mg/day) for NAE management will be enrolled. Comprehensive neuropsychological assessments and quality-of-life questionnaires will be conducted at baseline, week 6, week 12, and month 6 to document changes in cognitive function, depressive symptoms, and quality of life.

Enrollment

24 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Histologically confirmed diagnosis of ALK/ROS1-positive non-small cell lung cancer (NSCLC), stage IIIB/IV.
  • Currently receiving lorlatinib as part of the standard therapeutic regimen.
  • Documented neurocognitive adverse events (NAEs) attributable to lorlatinib.
  • Age >= 18 years.
  • ECOG performance status 0-2.
  • Ability to understand and sign informed consent.
  • Expected survival >= 6 months.
  • Planned initiation of vortioxetine as part of standard care.
  • Ability to complete neuropsychological tests and questionnaires in Spanish.

Exclusion criteria

  • Prior diagnosis of major cognitive impairment unrelated to cancer treatment.
  • Current use of another antidepressant that cannot be discontinued.
  • Uncontrolled major psychiatric disorder.
  • History of uncontrolled epilepsy or recent seizures.
  • Severe hepatic or renal impairment.
  • Known hypersensitivity to vortioxetine.
  • Participation in another clinical trial within the past 30 days.
  • Inability to provide informed consent.
  • Life expectancy < 3 months.
  • Contraindications to vortioxetine (e.g., concomitant MAOI use).
  • Prior vortioxetine use.
  • Severe psychiatric disorders or significant cognitive impairment unrelated to lorlatinib.

Trial contacts and locations

1

Loading...

Central trial contact

Felipe Canro, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems